|
Agent | Study | Phase | Protocol IDS |
|
PARP inhibitors | | | |
Olaparib | Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer | I/II | DFCI 09-293 |
EE7449 | An open-label, multicenter, phase 1/2 study of poly(ADP-Ribose) polymerase (PARP) inhibitor E7449 as single agent in subjects with advanced solid tumors or With B-cell malignancies and in combination with temozolomide (TMZ) or with carboplatin and paclitaxel in subjects With advanced solid tumors | I/II | E7449-E044-101 |
Olaparib | Phase Ib study of olaparib plus weekly carboplatin and paclitaxel in relapsed ovarian cancer | I/II | ISS22810034 |
Veliparib | Veliparib and topotecan for relapsed ovarian cancer with negative or unknown BRCA status | I/II | VeTo |
Rucaparib | Rucaparib(CO-338; formally called AG-014699 or PF-0136738) in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer | II | CDR0000593558 |
Veliparib | Veliparib and topotecan hydrochloride in treating patients with solid tumors, relapsed or refractory ovarian cancer, or primary peritoneal cancer | I/II | NCI-2011-00312 |
Veliparib | Veliparib monotherapy for relapsed ovarian cancer with BRCA mutation | I/II | Veli-BRCA |
Veliparib | Veliparib and floxuridine in treating patients with metastatic epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer | I | NCI-2012-02767 |
BKM120/olaparib | Phase I of BKM120/olaparib for triple negative breast cancer or high-grade serous ovarian cancer | I | 12-159 |
ABT-888 | ABT-888 in treating patients with malignant solid tumors that did not respond to previous therapy | I | NCI-2011-01472 |
ABT-888 | Carboplatin, paclitaxel, bevacizumab, and ABT-888 in treating patients with newly diagnosed stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer | I | NCI-2011-03730 |
ABT-767 | Study of ABT-767 in subjects with breast cancer 1 and breast cancer 2 (BRCA 1 and BRCA 2) mutations and solid tumors or high-grade serous ovarian, fallopian tube, or primary peritoneal cancer | I | M10-976 |
Veliparib | Veliparib, paclitaxel, and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction | I | NCI-2011-02500 |
Veliparib | Veliparib and liposomal doxorubicin hydrochloride in treating patients with recurrent ovarian cancer, fallopian tube cancer, primary peritoneal cancer, or metastatic breast cancer | I | CDR0000674917 |
Veliparib | Phase II study of veliparib in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who carry a germline BRCA 1 or BRCA 2 mutation | II | GOG-0280 |
Veliparib | Veliparib, oxaliplatin, and capecitabine in treating patients with advanced solid tumors | I | NCI-2011-02543 |
Olaparib | Olaparib in combination with carboplatin for refractory or recurrent women's cancers | I | 110022 |
Veliparib | Veliparib, doxorubicin hydrochloride, and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer | I | NCI-2011-01977 |
AZD2281 | AZD2281 plus carboplatin to treat breast and ovarian cancers | I | 080092 |
|
VEGF inhibitors | | | |
RAD001 + Bevacizumab | Study of RAD001 and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancers | II | 09-01-RAD001BEV |
VB-111 (ANTI VEGF) | A phase I/II trial of VB-111 and paclitaxel for recurrent platinum-resistant müllerian cancer | I/II | VB-111-157 |
Dalantercept | Phase II trial of dalantercept to treat ovarian, fallopian tube, or primary peritoneal cancer | II | GOG-0170R |
Endostar | Endostar and/or cisplatin for treatment of malignant pleural effusion or ascites | II | SIM-90 |
Pazopanib | A randomized study of safety and efficacy of pazopanib and gemcitabine in persistent or relapsed ovarian cancer | II | 16153 |
Pazopanib | Phase I clinical and pharmacokinetic study of pazopanib in a population of frail elderly patients according SIOG criteria | I | 11GENE06 |
Pazopanib | Weekly paclitaxel with or without pazopanib in platinum-resistant or refractory ovarian cancer | II | MITO-11 |
Pazopanib | A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pretreated ovarian cancer | I/II | 3107000 |
Pazopanib | Pazopanib hydrochloride, paclitaxel, and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer | I/II | CDR0000703686 |
Pazopanib | Pazopanib and weekly topotecan in patients with recurrent ovarian cancer (TOPAZ) | I/II | PazTo_2010 |
Pazopanib | Paclitaxel with or without pazopanib hydrochloride in treating patients with persistent or recurrent ovarian epithelial, fallopian tube, or peritoneal cavity cancer | II | NCI-2011-03635 |
BIBF1120 | Doxorubicin + BIBF 1120 in patients with ovarian cancer | I/II | GYN10-149 |
BIBF1120 | Daily low dose chemotherapy and BIBF 1120 in advanced ovarian cancer | II | UCL/10/0470 |
BIBF 1120 | BIBF 1120 in bevacizumab-resistant, persistent, or recurrent epithelial ovarian cancer | II | Pro00033060 |
BIBF1120 | BIBF 1120 + carboplatin/pegylated liposomal doxorubicin (PLD) in patients with ovarian cancer (OC) | I | 1199.119 |
|
mTOR inhibitors | | | |
Temsirolimus | A study of combination of temsirolimus (Torisel) and pegylated liposomal doxorubicin (PLD, Doxil/Caelyx) in advanced or recurrent breast, endometrial, and ovarian cancer | I | UMCNONCO200902 |
Sirolimus | Sirolimus and vaccine therapy in treating patients with stage II–IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer | I | I 199911 |
Everolimus | Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | I | IRB 10-019 |
Temsirolimus | Temsirolimus, carboplatin, and paclitaxel as first-line therapy in treating patients with newly diagnosed stage III or stage iv clear cell ovarian cancer | II | NCI-2011-02653 |
Everolimus + bevacizumab | Bevacizumab with or without everolimus in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer | II | CDR0000640439 |
Temsirolimus + bevacizumab | Temsirolimus and bevacizumab in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer | II | NCI-2012-02086 |
Temsirolimus | Activity, tolerability, and safety of temsirolimus in women with ovarian cancer who progressed during previous platinum chemotherapy or within 6 months after therapy or advanced endometrial carcinoma | II | AGO-GYN 8 |
Temsirolimus | A Phase II study of sunitinib or temsirolimus in patients with advanced rare tumors | II | I206 |
|
Anti-HER2/Anti-EGFR | | | |
Lapatinib | Lapatinib and paclitaxel in treating patients with advanced solid tumors | I | UCSF CC#05591 |
TCMC-Trastuzumab | Safety study of 212Pb-TCMC-trastuzumab radio immunotherapy | I | AREVAMED01 |
Pertuzumab | A study of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer and low HER3 mRNA expression | II | MO28113 |
MGAH22 Anti HER2 | Safety study of MGAH22 in HER2-positive carcinoma | I | CP-MGAH22-01 |
Panitumumab | Carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer | II | GMIHO-008/2009_AG56 |
Panitumumab | Panitumumab and gemcitabine in relapsed ovarian cancer | II | WIH 20050782 |
OSI906 IGFR inhibitor | A study evaluating intermittent and continuous OSI-906 and weekly paclitaxel in patients with recurrent epithelial ovarian cancer (and other solid tumors) | I/II | OSI-906-202 |
|
Kinase inhibitors | | | |
Sorafenib | Efficacy and safety study of sorafenib with topotecan in patients with platinum-resistant recurrent ovarian cancer | II | TRIAS 2009 |
Sorafenib | Sorafenib and bevacizumab to treat ovarian, fallopian, and peritoneal cancers | II | 070058 |
Sorafenib | Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors | I | CTRC 11-71 |
Sunitinib | Sunitinib and hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy | I | NCI-2012-03112 |
Cabozantinib | Cabozantinib or paclitaxel in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer | II | NCI-2012-02058 |
AT13148 | Phase I study of AT13148, a novel AGC kinase inhibitor | I | CRUKD/12/001 |
VS-6063 | Phase I/Ib study of paclitaxel in combination with VS-6063 in patients with advanced ovarian cancer | I | VS-6063-101 |
|
Miscellanea | | | |
MK-1775 (Wee-1 inhibitor) | Study with Wee-1 inhibitor MK-1775 and carboplatin to treat p53 mutated refractory and resistant ovarian cancer | II | M10MKO/MK1775-009 |
MK-1775 (Wee-1 inhibitor) | A study of MK-1775 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for participants with platinum-sensitive ovarian tumors with the P53 gene mutation (MK-1775-004 AM4) | II | 1775-004 |
BKM 120 (mutate PTEN; PIK3CA inhibitor) | BKM120 in advanced, metastatic, or recurrent endometrial cancers | II | HCI47841 |
BYL719 (PI3KNASE inhibitor) | A phase Ib/II study of the combination of BYL719 plus AMG 479 in adult patients with selected solid tumors | I/II | CBYL719X2105J |
Cyclin dependent kinases 4 and 6 | An open label study of the efficacy and safety of PD0332991, a selective inhibitor of the cyclin dependent kinases 4 and 6 in patients with recurrent ovarian cancer demonstrating Rb proficiency and Low p16 expression | II | 11-003234 |
Triciribine (AKT inhibitor) | Triciribine and carboplatin in ovarian cancer | I/II | MCC-17035 |
LY2228820 (MAP KINASI) | A study of LY2228820 for recurrent ovarian cancer | I/II | 12517 |
Inhibitor AKT (GSK2110183) | Dose-finding study on platinum-resistant ovarian cancer | I/II | PKB116611 |
MEK inhibitor | Trial of MEK inhibitor and PI3K/mTOR inhibitor in subjects with locally advanced or metastatic solid tumors | I | EMR 200066-006 |
MSC2015103B or pimasertib (MEK inhibitor) | MSC2015103B in solid tumors | I | EMR 200064-001 |
MEK162 | A study of MEK162 and paclitaxel in patients with epithelial ovarian, fallopian tube, or peritoneal cancer | I | ARRAY-162-112 |
GSK2636771 | A Phase I/IIa, first time in human, study of GSK2636771 in subjects with advanced solid tumors with phosphatase and tensin homolog (PTEN) deficiency | I/II | 115717 |
OMP-54F28 (antagonist of the Wnt pathway | A dose escalation study of OMP-54F28 in subjects with solid tumors | I | 54F28-001 |
|